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ABSTRACT Deregulation of the expression of the genes that are involved in the control of the cell cycle impairs 
cellular differentiation and leads to cell death. This process can result in uncontrollable cell proliferation and, 
subsequently, cancer development. In this study, we examined the effect of the silencing of cancer-related genes 
by small interfering RNAs (siRNA) targeted at mRNA of Her2, cyclin B1 (CCNB1), and protein kinase C (PKC) on 
the proliferation of human cancer cells of different origins. Maximum silencing of CCNB1, Her2 (in KB-3-1, SK-
N-MC, MCF-7 cells), and PKC (in MCF-7 cells) was achieved 72 h after transfection of the corresponding siR-
NAs, and 12 days after the transfection, the initial levels of the target mRNAs were fully recovered. Silencing of 
Her2, CCNB1, and PKC differently effected the proliferation of the cell lines under study. The most pronounced 
antiproliferative action of the investigated siRNAs was observed in neuroblastoma SK-N-MC cells (3 – 10-fold 
reduction in the proliferation rate) even after the recovery of the initial levels of expression of the Her2, CCNB1, 
and PKС genes. The obtained data indicate that the CCNB1 and PKC genes can be used as targets in the develop-
ment of drugs for neuroblastoma treatment.
KEYWORDS neuroblastoma; siRNA; Her2; CCNB1; PKC; proliferation.
ABBREVIATIONS C – 2’-O-methylcytosine; U – 2’-O-methyluridine; siRNA – small interfering RNA; МТТ – 
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; PBS – phosphate buffered saline; FBS – fetal 
bovine serum.
INTRODUCTION
Malignant cell transformation is a complex process in-
volving both genetic disorders and failure in the regu-
lation of differentiation, apoptosis, and proliferation 
[1, 2]. The regulatory signal transduction network in a 
cell is cascade-like and consists of a number of dupli-
cating paths [3]. When silencing one of the cell factors 
that participate in signal transduction, its function can 
be compensated by the activation of alternative signal 
paths [3]. While on one hand this further complicates 
the search for adequate molecular targets , on the other 
hand, it makes it necessary to design anti-tumor cells 
that would provide an irreversible antiproliferative ef-
fect by “switching off” the synthesis of the protein fac-
tors localized at the points of interception of the regula-
tory paths.
Hyperexpression of normal genes or expression of 
their mutant variants encoding transcription factors, 
receptors, tyrosine kinases, and other regulatory pro-
teins can be behind the uncontrollable cell division 
upon cancer [2]. Suppression of the synthesis of these 
proteins may provide a positive effect and normalize 
cell proliferation [4–7].
Today, RNA interference is widely used both to 
study the role of genes in the regulation of the cell cy-
cle and to reveal potential targets for designing new 
therapeutical agents [8–10]. Specific and efficient si-
lencing of target genes can be achieved using chemi-
cally synthesized small interfering RNAs (siRNAs) 
[11]. The products of such genes as  Her2, cyclin B1 
(CCNB1), and protein kinase C (PKC) belong to dif-
ferent groups of proteins that participate in the regu-
lation of the cell cycle [8, 12, 13]. Earlier, it was ex -
perimentally demonstrated and clinically verified that 
disorders in the expression of these genes may result 
in the emergence of malignant tumors in humans [12, 
14–18]. The level of amplification and expression of 
these genes in breast or ovarian cancer cells, or cancer 
cells in other human organs, is considerably higher 
than that in the normal cells of these organs [14, 17–30 | ACTA NATURAE |  VOL. 3  № 3 (10)  2011
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32]. Moreover, high levels of expression of the  Her2, 
CCNB1, and PKC genes correlate with dire prognosis: 
three-year survival rate, and the recurrence-free pe-
riod shortens [17, 18, 22–25, 30].
The Her2 gene (also known as c-erb-B2 and neu) en-
codes a transmembrane glycoprotein possessing tyro-
sine kinase activity and belonging to the family of hu-
man epidermal growth factor receptors, which play a 
significant role in the regulation of the proliferation, 
differentiation, and mobility of human epitelial cells 
[33, 34]. A level of Her2 gene expression considerably 
higher than the normal level was detected in the cells of 
humans with breast, endometrial, uterine neck, ovar-
ian, fallopian tube, and lung cancer [25, 29, 30].
Cyclin B1 encoded by the CCNB1 gene is a regula-
tory subunit of the cyclin-dependent kinase complex 
(CDK1) that regulates the transition from phase G2 of 
the cell cycle into phase M [35]. Hyperexpression of the 
CCNB1 gene usually does not immediately result in cell 
cycle disorder, which causes the accumulation of mu-
tations in a cell [36]. An increased expression level of 
this gene, which is typical of benign and malignant hu-
man prostate tumors [37], is often the reason for aneu-
ploidy [38]. Disturbance in the CCNB1 gene expression 
could be regarded as an early warning in malignant cell 
transformation [17].
Protein kinase C encoded by the  PKC gene is ex-
pressed in many human tissues and organs; it plays an 
important role in the transduction of the regulatory 
signals that activate various cell functions, including 
proliferation [39, 40]. A level of PKC gene expression 
higher than the normal level was detected in human 
cancer cells of different origins [18, 19].
It has been known that silencing of the same gene 
in tumor cells of different tissue origins may result in 
various antiproliferative effects [41]. This determines 
the necessity for comparing the antiproliferative ac-
tion of siRNAs in different human tumor cell lines. 
It was earlier demonstrated that siRNAs targeted at 
mRNAs of the Her2, CCNB1, and PKC genes efficient-
ly silence the target genes and have an antiprolifera-
tive effect on human cancer cells for 5 days following 
transfection [41].
In this study, we assessed the long-term conse -
quences of short-term silencing of Her2, CCNB1, and 
PKC on the proliferation and morphology of human 
tumor cells. We demonstrated that siRNAs that are 
homologous to mRNAs of the Her2, CCNB1, and PKC 
genes silence these genes, attaining maximum effect 
(up to 4–22% of the control level) 72 h after transfec-
tion. These siRNAs demonstrated different efficiencies 
of deceleration of the division of human tumor cells of 
different tissue origins. We found that the antiprolif-
erative effect of siCyc and siPKC in SK-N-MC neu-
roblastoma cells is retained even after the initial levels 
of target gene expression have been recovered. The 
data obtained permit the reasonable assumption that 
the CCNB1 and PKC genes play a key role in sustain-
ing a high proliferation rate of neuroblastoma cells, 
whereas their short-term silencing results in change 
in signal transmission paths and normalization of the 
rate of cell division. Thus, the CCNB1 and PKC genes 
in SK-N-MC cells can serve as potential efficient tar-
gets for the agents targeted at neuroblastoma, includ-
ing siRNAs.
EXPERIMENTAL
siRNAs
All the oligonucleotides that were used to form siRNA 
duplexes were synthesized at the Laboratory of RNA 
Chemistry, Institute of Chemical Biology and Funda-
mental Medicine, Russian Academy of Sciences, Si-
berian Branch using the solid-phase phosphiteamide 
method on an automatic synthesizer ASM-102U (Bi-
osset, Russia) and extracted using high-efficiency re-
versed phase chromatography. The nuclease-sensitive 
sites in siRNA were protected by introducing 2’-O-Ме-
analogues of ribonucleotides into the siRNAs using the 
algorithm described earlier [42, 43]. According to the 
data of electrophoresis in polyacrylamide gel under de-
naturating conditions, the purity of the oligoribonucle-
otides was at least 95%. The following siRNAs were used 
in the present study: siHer homologous to the region 
1297–1317 of mRNA of the human Her2 gene (sense 
strand 5’-GCAGUUACCAGUGCCAAUAUU-3’, anti-
sense strand 5’-UAUUGGCACUGGUAACUGCCC-3’); 
siCyc  homologous  to  the  region  189–209  of 
mRNA of the human  CCNB1 gene (sense strand 
5’-CACCAGGAACUCGAAAAUUUU-3’, antisense 
strand  5’-AAUUUUCGAGUUCCUGGUGAC-3’); 
and siPKC homologous to region 1079–1099 of 
mRNA  of  the  human   PKC  gene  (sense  strand 
GCGGCCAGAGAAGGAAAAAUU-3’, antisense 
strand 5’-UUUUUCCUUCUCUGGCCGCUG-3’), 2’-O-
Me-modified units are underlined. siScr (sense strand 
5’-CAAGUCUCGUAUGUAGUGGUU-3’, antisense 
strand 5’-CCACUACAUACGAGACUUGUU-3’) with-
out significant homologies with the nucleotide sequenc-
es of mRNAs of mouse, rat, and human genes was used 
as the negative control. siRNAs were selected using the 
BioPredSi software [44]. siRNAs were obtained via fu-
sion of the antisense and sense strands in a buffer of 
15 mM HEPES-KOH pH 7.4, 50mM potassium acetate, 
and 1 mM magnesium acetate. To perform this proce-
dure, equimolar mixtures of oligoribonucleotides (sense 
and antisense strands) were incubated for 2 min at 900С 
and slowly cooled to room temperature.RESEARCH ARTICLES
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Cell cultures and siRNA transfection
Cell lines of human uterine neck carcinoma KB-3-1, 
SK-N-MC neuroblastoma, and MCF-7 breast adeno-
carcinoma were obtained from the collection of the In-
stitute of Cytology of the Russian Academy of Sciences 
(St. Petersburg, Russia). The cells were cultivated in a 
DMEM medium (Dulbecco’s Modified Eagle Medium) 
containing 10% of fetal bovine serum (FBS), 100 u/ml 
of penicillin, 100 µg/ml of streptomycin, and 0.25 µg/ml 
of amphotericin at 37оC in humid atmosphere with 5% 
CO2 content. Twenty-four hours prior to the experi-
ment, the cells in the phase of exponential growth were 
seeded in 6-well plates: KB-3-1 – 4 × 104, SK-N-MC – 
2 × 105, MCF-7 – 8 × 104 cells/well or in 24-well plates: 
KB-3-1 –105, SK-N-MC – 1.25 × 105, and MCF-7 – 
1.5 × 105 cells/well and allowed to adhere overnight. 
The cells were transfected with siRNA at a concen-
tration of 200 nM; Lipofectamine 2000ТМ (Invitrоgen, 
United States) or OligofectamineТМ (Invitrоgen, United 
States) for SK-N-MC cells were used as transfection 
agents, in accordance with the manufacturer’s protocol. 
The levels of specific mRNAs were determined 1–5, 
7, 10, and 12 days after transfection. The cells treated 
only with a transfection agent or siScr/lipofectamine 
(oligofectamine) complex were used as the control. 
During the experiment, the cells were reseeded once in 
3–4 days to maintain the exponential growth.
Real-time reverse transcription PCR (RT-PCR)
The total RNA was extracted from the cells using the 
SDS-phenol method [45]. Reverse transcription (RT) 
reaction was carried out in a 20 µl mixture contain-
ing 1 µg of total RNA, 5 µM of the oligo(dT15) primer, 
50 mM of Tris-HCl, pH 8.3, 75 mM of KCl, 3 mM of 
MgCl2, 0.5 mM of dNTP, 5 mM of dithiothreitol, and 
10 U of M-MLV reverse transcriptase from the Molo-
ney murine leukemia virus. The reaction mixture was 
incubated at 42 оC for 1 h. The resulting cDNA was am-
plified in a reaction mixture (volume 20 µl) containing 
1 µl of cDNA, 10 mM of Tris-HCl, pH 8.3, 50 mM of KCl, 
1.5 mM of MgCl2, 0.01% Tween-20, 0.25 mM of each 
dNTP, 0.25 µM of each primer, 0.5 mM of EvaGreen 
(Biotium, United States), and 2 U of thermostable DNA 
polymerase Thermus aquaticus (produced at the In-
stitute of Chemical Biology and Fundamental Medi-
cine, Siberian Branch, Russian Academy of Sciences). 
Real-time PCR was carried out on a Bio-Rad iQ5 Mul-
ticolor Real-Time PCR Detection System instrument 
according to the following scheme: one cycle – 3 min, 
95оC, 40 cycles – 30 s, 95оC, 30 s – 58оC, 30 с – 72оC. The 
amount of mRNA of each gene was standardized per 
the amount of mRNA of β-actin, since the level of ex-
pression of this gene is relatively constant for different 
types of cells. The relative level of gene expression was 
determined using the Bio-Rad iQ5 2.0 software (Bio-
Rad Laboratories Inc., United States).
The following DNA primers were used in the present 
study:
Her2 forward – 5’-AGCAATGGTGTCAGTATCCAG-
GCT-3’, 
Her2 reverse – 5’-TGCAAATGGACAAAGTGGGT-
GTGG-3’, 
CCNB1 forward – 5’-AGGAAGAGCAAGCAGTCA-
GACCAA-3’, 
CCNB1  reverse  –  5’-GCAGCATCTTCTT -
GGGCACACAAT-3’, 
PKC forward – 5’-GCTGTCTTTCACGATGCCCC-3’, 
PKC reverse – 5’-CACCCGACGACCCTGAGAGA-3’, 
β-actin forward– 5’-ACCAACTGGGACGACATGGA-
GAAA-3’, 
β- actin reverse – 5’-TTAATGTCACGCACGATTTC-
CCGC-3’.
MTT test
The number of living cells was determined us -
ing the colorimetric method based on oxidation of 
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium 
bromide (MTT) in mitochondria of living cells [46]. On 
day 6 after siRNA transfection, the cells were seeded 
from the 6-well plate to a 96-well plate, with density 
being 1.5 × 103 (KB-3-1), 7.5 × 103 (SK-N-MC), and 3 × 
103 cells/well (MCF-7), followed by incubation over a 
period varying from 1 to 6 days at 37оC. Then, the MTT 
solution was added to the cells until the concentra -
tion reached 0.5 mg/ml. After 3 h, the culture medium 
was removed; the resulting formazan crystals were 
dissolved in dimethyl sulfoxide (100 µl/well), and the 
optical density of the solution was measured on a Mul-
tiscan RC multichannel photometer (Labsystems) at 
wavelengths of 570 and 630 nm. The results were rep-
resented as the relative proliferation rate, i.e., the rate 
of cell division in the sample standardized to the cell 
division rate in the control (taken as 100%). The prolif-
eration rate was calculated using the following formu-
la: V = (D12 – D7)/(Δt), where D12 and D7 are the optical 
densities in the wells 12 and 7 days after transfection, 
respectively; Δt is the time interval of cell observation 
(i.e., 12–7 = 5 days).
Microscopic analysis 
For the microscopic analysis, SK-N-MC neuroblastoma 
cells after transfection with siRNA preparations for 48 h 
were seeded (105 cells/well) in round coverslips with a 
diameter of 15 mm, which were placed into the wells of 
a 24-well plate. The oligofectamine-only treated cells, 
intact cells, and the cells transfected with siScr (controls) 
were incubated for 24, 48, and 72 h; whereas the cells 
transfected with siRNA siCyc, siPKC were incubated 32 | ACTA NATURAE |  VOL. 3  № 3 (10)  2011
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for 3, 5, 7, and 12 days. After the incubation, the cells 
were washed with 0.5 ml of DMEM and immobilized 
without taking them off the coverslip with 4% para-
formaldehyde in a DMEM medium. Cell preparations 
were then washed with PBS, treated with acetone for 
5 min, and washed with PBS, again. Then, hematoxylin 
or Feulgen staining [47] was carried out, and the cells 
were incorporated into polystyrene. The stained prepa-
rations of SK-N-MC neuroblastoma cells were studied in 
a DM2500 light microscope with a DFC420 digital cam-
era (Leica, Germany). Mitosis calculation was performed 
upon zooming ×40.
RESULTS
The Her2, CCNB1, and PKC genes encoding the most 
significant regulatory proteins of the cell cycle were 
selected as targets for siRNAs, since their hyperex-
pression is frequently associated with the emergence 
of various tumor diseases.
Analysis of the expression levels of the Her2, CCNB1, 
and PKC genes in KB-3-1, SK-N-MC, and MCF-7 cell 
lines after transfection with corresponding siRNAs
The expression of target genes was determined in the 
following cell lines: KB-3-1 (uterine neck carcinoma), 
SK-N-MC (neuroblastoma), and MCF-7 (breast adeno-
carcinoma). We had previously detected a high mRNA 
level of the CCNB1 gene in these cell lines and a slight-
ly lower mRNA level of the Her2 gene; an increased 
mRNA level of the PKC gene was revealed only in 
MCF-7 cells [41].
The effect of siRNAs on the expression of target genes 
was analyzed on the basis of the following scheme: siR-
NA at a concentration of 200 nm was transfected to the 
cells; OligofectaminТМ (SK-N-MC) and Lipofectamin 
2000ТМ (other cell lines) being used as transfection 
agents. 1–12 days after transfection (upon long-term 
experiments, the control cells were reseeded once per 
3–4 days), real-time PCR was used to extract the total 
RNA from the cells and determine the level of specific 
mRNAs; the β-actin gene was used as an internal stand-
ard. The specificity of the siRNA action was inspected on 
the basis of the retention of the mRNA levels of β-actin 
and its nonhomologous target genes (Fig. 1).
As can be seen in Fig. 1, all siRNAs efficiently and 
specifically silence their target genes in the cell lines 
used; maximum silencing (up to 97–99%) being ob-
served 72 h after transfection. siHer decreased the 
expression of the Her2 gene only, having no effect on 
the expression of the CCNB1 and PKC genes, as well as 
that of β-actin. Similar results were obtained when us-
ing siRNA siCyc and siPKC. Random-sequence siRNA 
(siScr) caused no changes in the expression level of tar-
get genes, as well.
siHer and siCyc reduced the mRNA levels of the 
Her2 and CCNB1 genes in all of the cell lines used. 
Seventy-two hours after transfection, the mRNA level 
of the Her2 gene was equal to 15% in KB-3-1 cells, 4% 
in SK-N-MC cells, and 7% in the MCF-7 cell line with 
respect to the control. The mRNA level of the CCNB1 
gene in the КВ-3-1, SK-N-MC, and MCF-7 cells 72 h 
after transfection with siCyc decreased to 22, 16, and 
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Fig. 1. Relative levels of Her2, CCNB1 and PKC mRNAs 
in KB-3-1 (A), SK-N-MC (B), and MCF-7 (C) cells 1 – 
12 days after siRNAs (200 nM) transfection. The level of 
β-actin mRNA was used as an internal standard. Mean 
values obtained from three independent experiments. 
The standard error of the mean < 10%. Control/gene(s) 
is the relative mRNA level of genes in the control cells. 
siRNA/gene(s) is the relative mRNA level of gene(s) in 
the cells after siRNA transfection.RESEARCH ARTICLES
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18%, respectively, as compared to the control. siPKC 
transfection reduced the mRNA level of the PKC gene 
in MCF-7 cells to 14% (Fig. 1). The data obtained at-
test to the fact that siHer, being an inhibitor of the 
Her2 gene, has the highest efficiency in SK-N-MC 
and MCF-7 cell lines, whereas siCyc most considerably 
decreases the mRNA level of the CCNB1 gene in SK-
N-MC and MCF-7 cells (Fig. 1). Starting with day 4 af-
ter transfection, the mRNA level of all genes gradually 
increased and returned to the initial value by day 7–12 
after transfection (Fig. 1).
As can be seen in Fig. 1, the kinetic curves of the rel-
ative mRNA level of the Her2, CCNB1, and PKC genes 
after transfection with specific siRNAs are U-shaped. 
The following regions can be visually isolated in each 
curve: a region corresponding to the decrease in the 
level of specific mRNA (days 1–3), the region where its 
amount increases (days 3–7), and the region in which 
the amount of target mRNA is stabilized at a level cor-
responding to its level in the control cells (days 7–12). 
The gradual recovery of the initial mRNA level in cells 
is probably associated with cell division, which results 
in the reduction of siRNA concentration in cytoplasm, 
and, therefore, in attenuation of the RNA interference 
effect.
Thus, the siRNAs used provide efficient silencing of 
the Her2, CCNB1 and PKC genes in human tumor cells. 
The analysis of their expression at the mRNA level has 
demonstrated the specificity of the action of the siR-
NAs selected.
Proliferation of KB-3-1, SK-N-MC, and MCF-
7 cell lines after the recovery of the initial level 
of Her2, CCNB1, and PKC gene expression
It was shown earlier that the observed anti-prolifera-
tive effect of the siRNAs under study is conditioned by 
the retardation of cell division rather than their death 
[41]. In this study, we analyzed the changes in the pro-
liferation rate of the cells after the initial level of target 
gene expression was recovered. The dependence of the 
proliferation rate of KB-3-1, SK-N-MC, and MCF-7 
cells on the expression level of Her2, CCNB1, and PKC 
was estimated using the MTT test over a period rang-
ing from day 7 to day 12 after transfection of the cor-
responding siRNA (200 nm); the cell proliferation rate 
in the control samples was taken as 100% (Table 1). As 
expected, transfection of nonspecific siScr does not re-
sult in a reliable change in the cell proliferation rate.
The proliferation rate of the КВ-3-1 cell line after the 
initial expression levels of target genes (Her2, CCNB1) 
is virtually the same as that of the control cells. On the 
contrary, the proliferation rate of SK-N-MC and MCF-
7 cells remained low even after the expression of target 
genes (Her2, CCNB1) was recovered. Thus, after siHer 
transfection, the division rate of SK-N-MC and MCF-7 
cells over the period of 7–12 days was equal to 36 and 
78% of its level in the control, respectively. The prolif-
eration rate of SK-N-MC and MCF-7 cells exposed to 
the action of siCyc remained at a level of 14 and 73% of 
its level in the control, respectively; that of siPKC was 
equal to 9 and 79% (Table 1). It should be mentioned 
that siPKC has the most pronounced and longest anti-
proliferative effect (10-fold deceleration of the division 
rate) on SK-N-MC neuroblastoma cells, in which the 
expression of the PKC gene cannot be detected with 
the methods used (see [41]). siHer and siCyc had also 
the most pronounced antiproliferative effect on SK-N-
MC line cells. Thus, specific silencing of the genes that 
are responsible for cell-cycle regulation is capable of 
considerably decelerating and even terminating SK-
N-MC cell division.
As can be seen in Table 1, the cell lines used can be 
conventionally divided into three groups: the cells in 
which the proliferation rate is completely recovered 
(КВ-3-1); those in which the proliferation rate re -
mains considerably reduced (SK-N-MC); and those in 
which the proliferation rate remains insignificantly re-
duced, after the recovery of the initial mRNA level of 
the target genes. The temporary silencing of the Her2, 
CCNB1, and PKC genes is unlikely to result in irrevers-
ible changes in the regulation paths of КВ-3-1 cell divi-
sion; therefore, the cell proliferation rate is recovered, 
together with the recovery of the mRNA levels of these 
genes. The situation is different with SK-N-MC cells: 
the temporary silencing of these genes apparently re-
sults in irreversible changes in the paths of proliferation 
regulation; therefore, the proliferation rate remains 
Table 1. The effect of siRNAs on the proliferation  
of KB-3-1, SK-N-MC, and MCF-7 cells
siRNA, 
200 nM
Proliferation rate*, %
KB-3-1 SK-N-MC MCF-7
Control** 100 ± 7 100 ± 6 100 ± 3
SiScr 113 ± 10 90 ± 7 93 ± 6
SiHer 123 ± 8 36 ± 9 78 ± 2
SiCyc 112 ± 9 14 ± 4 73 ± 2
SiPKC 117 ± 14 9 ± 3 79 ± 2
* The average values over the results of three independ-
ent experiments ± the standard deviation are presented.
** Cells treated with a transfection agent only.34 | ACTA NATURAE |  VOL. 3  № 3 (10)  2011
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considerably reduced even after the mRNA levels of 
the target genes are recovered. In MCF-7 cells, sup-
pression of proliferation has an intermediate character; 
the division rate is reduced, although not completely. 
This fact likely demonstrates that the role of the Her2, 
CCNB1, and PKC genes in the paths of proliferation 
regulation differs for these cell lines in terms of its sig-
nificance.
The results obtained attest to the fact that the PKC 
and CCNB1 genes are the most efficient targets for 
gene-targeted action on SK-N-MC neuroblastoma cells 
and CCNB1 breast cancer cells, respectively. In SK-N-
MC cells, the antiproliferative effect of silencing the 
CCNB1 and PKC genes is considerably higher than that 
conditioned by siHer (Table 1).
Effect of CCNB1 and PKC gene silencing 
on the morphological characteristics 
of the SK-N-MC cell culture
The study demonstrated that the most efficient si-
lencing of the CCNB1 and PKC genes is observed in a 
SK-N-MC human neuroblastoma cell culture (Table 1); 
therefore, we performed a microscopic study of the 
changes in the morphology and division of cells of this 
line under the action of siCyc and siPKC.
A SK-N-MC neuroblastoma cell culture treated with 
OligofectaminТМ (control) after 24 h of incubation is rep-
resented by different cell types (Fig. 2). A portion of the 
cells form a monolayer with “growth islets,” another 
part of the cells forms small, dense globular aggregates. 
The “growth islets” of different sizes consist of flat po-
lygonal mononuclear cells with homogeneously stained 
cytoplasm and non-stained vacuoles (Fig. 2A) connect-
ing into networks on the coverslip surface. In most cas-
es, the “growth islets” have appreciably distinguish-
able boundaries; a tendency towards merging being 
observed. Small spherical cells with a large nucleus, an 
intensely stained cytoplasm, and smooth surface can be 
sparsely found in the “growth islets.” Spherical cell ag-
gregates are located on the coverslip both individually 
and in clusters, their appearance reminding mulberries. 
Aggregation cells are small, intensely stained, with nee-
dle-like or rounded sprouts on the surface; cells with 
a smooth surface occur, as well (Figs. 2B, C). The cells 
lie tightly against each another, making it impossible 
to count them on total preparations. The third type of 
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Fig. 2. Morphol-
ogy of neurob-
lastoma SK-
N-MC cells on 
coverslips (total 
preparations). 
A – “islet” cells; 
B, C – dense 
spherical cell ag-
gregations; D – 
neuron-like cell; 
E – fusiform cell; 
F – mitoses (indi-
cated by arrows) 
in the culture 
cells 5 days after 
siCyc (200 nM) 
transfection; the 
sidebar shows 
the divergence 
of the mitotic 
chromosomes. 
Staining by he-
matoxylin.RESEARCH ARTICLES
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cells that are present in the SK-N-MC neuroblastoma 
cell culture is large spread cells of neuron-like shape 
with a pale stained vacuolized cytoplasm (Fig. 2D). The 
cells contain 1–2 nuclei; multinuclear variants occur, 
as well. Neuron-like cells are mostly localized between 
the “islet” cells and stand out against the general back-
ground by their isolation. Only in extremely rare cases 
do they contact with the cells of other types, and even 
if they are localized in the center of the “growth islets,” 
the space around them is empty.
Small, strongly elongated spindle- or needle-shaped 
cells with sparse vacuoles in the cytoplasm also occur 
in the SK-N-MC neuroblastoma cell culture (Fig. 2E). 
Thus, four morphological types of cells are revealed in 
preparations of SK-N-MC neuroblastoma cells at the 
light-optical level, no transition forms being observed 
upon the used method of analysis.
When incubating SK-N-MC cells treated with 
OligofectaminТМ for 24–72 h, the morphological char-
acteristics of the cell types remain constant; all of the 
described variants being revealed on the coverslips. 
A considerable increase in the total amount of cells 
on coverslips is observed due to the “islet” cells; the 
“growth islets” merge, and by the end of day 3 of incu-
bation these cells represent the main mass of the cul-
ture. Multiple mitoses are observed in the “islet” SK-
N-MC culture cells during the incubation for 24–72 h 
(Table 2). The variety of sizes of spherical cell aggre-
gates, neuron-like and spindle-like cells does not no-
ticeably change.
The comparison of preparations of intact SK-N-MC 
cells and OligofectaminТМ-treated cells revealed no ob-
servable changes in the morphological characteristics 
of the cells. Treatment with a transfection agent did 
not result in the emergence of new variants of cells or 
a noticeable change in their ratio. Transfection of SK-
N-MC cells with all siRNAs did not result in the emer-
gence of new morphological cell types, either: all prep-
arations contained the cell varieties described above at 
all incubation periods. Transfection of SK-N-MC cells 
with siScr did not result in any noticeable changes in 
the ratio between different types of cells during 72 h 
of incubation, as compared with preparations of the 
oligofectamin-treated culture.
A study of the preparations of SK-N-MC neuroblas-
toma cells obtained after different time intervals after 
transfection revealed distinct morphological signs of 
the effect of siCyc and siPKC on the vital activity of 
the cells. The “seeding” dosage being equal, the cells ei-
ther OligofectaminТМ-treated or transfected with siScr 
almost completely filled the surface area of the cov-
erslip after 3 days of incubation (Figs. 3B,D), whereas 
transfection with siCyc or siPKC abruptly decelerated 
cell division, their number on the coverslip on the same 
day being incomparably smaller (Figs. 3E,G). The cells 
transfected with siCyc and siPKC were incubated for 
12 days (Figs. 3F,H), whereas it was necessary to reseed 
the cells transfected with siScr and the control cells 
once in 3 days. The differences in the growth rate and 
necessity to reseed the control and siScr transfected 
cells rendered it impossible to compare the morpho-
logical characteristics of the culture transfected with 
siCyc and siPKC with the control preparations after 
5–12 days of incubation. Only the preparations incu-
bated for 72 h after transfection could be compared. 
А B
C D
E F
G H
Fig. 3. Neuroblastoma SK-N-MC cells on a coverslip (total 
preparations). Control cells (only transfection reagent 
treatment): A – 1 day of incubation, B – 3 days of in-
cubation. Transfection with 200 nM siScr: C – 1 day of 
incubation, D – 3 days of incubation. Transfection with 
siCyc: E – 3 days of incubation, F – 12 days of incubation. 
Transfection with siPKC: G – 3 days of incubation, H – 12 
days of incubation. Staining with hematoxylin. Size bar is 
200 µm.36 | ACTA NATURAE |  VOL. 3  № 3 (10)  2011
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The preparations of SK-N-MC cells transfected with 
siCyc and siPKC during the period contained an incom-
parably smaller number of “islet” cells, in comparison 
to the control. The major part of the population was 
represented by small, intensely stained cells from the 
globular aggregates, which included several cells at a 
time. Against the background of a decreasing number 
of “islet” cells, the relative number of neuron-like and 
fusiform cells was increasing. Similar to events in the 
control preparation, mitoses were revealed mostly in 
the “islet” cells; their number abruptly decreasing, es-
pecially if compared with the preparations transfected 
with siScr (Table 2).
Thus, 72 h after transfection with siCyc and siPKC, 
the mitotic activity of “islet” cells is considerably de-
creased in neuroblastoma cells and their number de-
creases; therefore, the ratio between the morphological 
types of culture cells changes and the share of neuron-
like and fusiform cells increases.
Late effects (days 5–12) of the transfection of neu-
roblastoma cells with siCyc and siPKC differed to a 
certain extent. When using siCyc, the number of mi-
toses increased 5 days after transfection and remained 
at the same level over the entire observation period 
(Table 2). The cells at the mitosis stage were mostly 
revealed among “islet” cells (Fig. 2E), their number 
increasing, while the number of spherical cell aggre-
gates, neuron-like and fusiform cells had not noticeably 
changed. It should be noted that even after 12 days of 
incubation, the number of neuroblastoma cells on the 
coverslips and the number of “islet” cells were appre-
ciably smaller than that in the control 72 h after the 
transfection (Fig. 3B,D,F). Transfection of neuroblas-
toma cells with siPKC resulted in a more prolonged 
decrease in the mitosis number; its growth being re-
corded only 7 days after transfection. It continued until 
the end of observations (Table 2). Similar to the case of 
transfection with siCyc, mitoses were revealed mostly 
in the islet cells; their number increasing during the 
incubation. Five days after transfection with siPKC, 
the relative increase in the number of neuron-like and 
fusiform cells noted after 3 days remained constant; 
the number of spherical cell aggregations also did not 
change. The islet cells comprised the major part of SK-
N-MC neuroblastoma cells 7 and 12 days after trans-
fection; their number increased intensely due to the 
active mitotic division (Table 2). The density of cells on 
the coverslip 12 days after the transfection was at a 
maximum and exceeded that in the control and upon 
transfection with siCyc (Fig. 3B,D,F,H). Thus, transfec-
tion with siPKC results in a more prolonged blocking 
of mitotic division of SK-N-MC neuroblastoma cells, in 
comparison with siCyc transfection; however, further 
growth in the number of mitoses is more pronounced 
and results in a more intense cell culture growth. The 
analysis of the morphological characteristics of SK-
N-MC neuroblastoma demonstrates that “islet cells” 
comprising the main part of the cell population, their 
division being suppressed, are the main target of si-
Cyc and siРКС. The effect of siPKC appears to be more 
complex as compared with that of siCyc, requiring fur-
ther investigation. The results of a microscopic study 
of SK-N-MC cell growth after silencing of the CCNB1 
and PKC genes (Fig. 3) agree well with the data on the 
effect of this silencing on the proliferation rate of these 
cells (Table 1).
DISCUSSION
Today, interfering RNAs are regarded as potential 
therapeutic agents; a number of preparations based 
on them have been going through different stages of 
clinical trials [48]. An urgent problem is revealing the 
targets in which the short-term silencing results in irre-
versible consequences for a cancer cell, such as terminal 
differentiation, apoptosis, or long-term suppression of 
their proliferation. An appreciably large body of data 
on successful temporal silencing of the genes responsi-
ble for the emergence of oncologic diseases, including 
the Her2, CCNB1, and PKC genes, has been published 
recently [4, 6, 7, 49]. It has been demonstrated that this 
silencing results in a decrease in the proliferation rate 
of cancer cells; however, most experiments were con-
fined to incubation of up to 96 h, whereas the fall in 
the mRNA level of the target gene under the action of 
siRNA is retained for up to 4–5 days. There had been 
no data concerning the duration of the effect of siRNA 
Table 2. The number of mitoses in SK-N-MC cells 
1–12 days after transfection with siCyc and siPKC 
(200 nm)
Day
Number of mitoses per 1,000 cells
Control* SiScr SiCyc SiPKC
Control 
without 
transfect-
ing agent
1 14 ± 5 16 ± 8 - - -
2 40 ± 16 25 ± 7 - - 22 ± 15
3 21 ± 10 33 ± 12 15 ± 11 16 ± 7 -
5 - - 30 ± 12 20 ± 11 -
7 - - 28 ± 6 35 ± 5 -
12 - - 30 ± 6 49 ± 14 -
* Cells treated with a transfection agent only.
(-) – not determined.RESEARCH ARTICLES
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on Her2, CCNB1, and PKC gene expression; therefore, 
we were the first to study the changes in the expres-
sion level of these genes 12 days after transfection with 
specific siRNAs. We were able to demonstrate that a 
maximum decrease in the expression level of the Her2, 
CCNB1, and PKC genes in KB-3-1, SK-N-MC, and 
MCF-7 cells is observed 72 h after siRNA transfection. 
The silencing of these genes, as it was earlier shown in 
[41], slows to a different extent the proliferation of tu-
mor cells from day 3 to day 7 of their cultivation after 
siRNA transfection. The analysis of the kinetics of the 
changes in the levels of specific mRNAs has demon-
strated that the initial mRNA levels are recovered as 
early as on day 5–day 7 after a single transfection with 
the corresponding siRNA, which is likely determined by 
the lifetime of siRNA in a cell (Fig. 1). The duration of 
the antiproliferative effect of siRNA in various cell lines 
considerably varies. The determination of the cell prolif-
eration rate over a period of day 7–day 12 after siRNA 
transfection demonstrated that after the initial level of 
the target gene expression is recovered, the prolifera-
tion rate of КВ-3-1 cells does not differ from the rate 
of cell growth in the control (that of nontreated cells, 
that of the cells subjected to the action of the transfec-
tion agent only, and those transfected with a random 
siRNA (SiScr)). The growth of MCF-7 cells transfected 
with specific siRNAs remained low to a certain extent as 
compared with the control. Thus, regardless of the pro-
nounced antiproliferative effect of siRNA preparations 
revealed, in order to limit the growth of these cell lines, 
it is necessary to sustain the decreased level of target 
gene expression. This can be achieved by additional in-
troduction of the corresponding siRNA into the cells or 
using short interfering hairpin RNA (shRNAs), which 
are expressed immediately in the target cells after their 
transduction with recombinant viruses (adeno-, adeno-
associated , lenti- and retroviruses). However, the issue 
of safety in using recombinant viruses for therapeutic 
purposes remains far from settled [50–52].
We found that the temporary silencing of the Her2, 
CCNB1, and PKC genes in a SK-N-MC cell culture re-
sults in considerable slowing of cell division even after 
the initial mRNA level of target genes is recovered (Ta-
ble 1). The CCNB1 and PKC genes serve as the most ef-
ficient target to achieve long-term suppression of pro-
liferation in SK-N-MC neuroblastoma cells (Table 1). 
The pronounced antiproliferative effect (5–10 times) 
of the short-term silencing of these genes remains for 
up to 12 days of incubation. It should be mentioned 
that the long-term antiproliferative effect of siPKC on 
SK-N-MC cells is quite unexpected, since no hyperex-
pression of the PKC gene is observed in these cells [41]. 
Nevertheless, the long-term antiproliferative effect of 
this specific inhibitor in SK-N-MC cells has been dem-
onstrated; the elucidation of its reasons requires ad-
ditional studies.
The proliferation rate of SK-N-MC cells remains at a 
considerably low level even after siCyc and siPKC have 
been removed from the cells and the level of their tar-
get genes returns to the initial level. This result is rath-
er unexpected. It appears that this phenomenon can 
be interpreted taking into account the specific pattern 
of gene expression in cells of neuronal origin (to which 
SK-N-MC cells belong), the changes in the expression 
pattern under the action of the temporary silencing of 
target genes, and its subsequent reactivation. Thereby, 
even a short-term expression inhibition of the CCNB1 
or PKC gene is likely to result in a very slow recovery 
of the cell proliferation rate (or in its complete block-
ing) even after the initial level of the products of each 
target gene is recovered. It is already known that a de-
ficiency in protein p53 is observed in this cell line; i.e., 
they do not contain the most important participant of 
the apoptosis induction chain, which appears to play a 
significant role in their uncontrollable proliferation [53]. 
It is possible that the absence of this participant in the 
regulatory cascade is one of the key reasons behind the 
difference between the consequences of a short-term 
inhibition of CCNB1 and PKC gene expression in this 
cell line and the other ones that were used; their pro-
liferation rate having recovered after the level of the 
target gene had returned to its initial level. It would 
be of interest to study the joint action of siRNAs and 
p53 inhibitors on the proliferation of cells of different 
lines. As shown by the results obtained, after the in-
hibition of CCNB1 and PKC gene expression in a SK-
N-MC cell culture, the share of neuron-like and fusi-
form cells characterized by a lower mitotic activity as 
compared with other morphological cell types in the 
culture was high to a certain extent. An increase in the 
share of these cells may attest to the induction of the 
initial events of cell differentiation (either reversible or 
irreversible), which may also be one of the reasons for 
the so prolonged antiproliferative effect of the selected 
siRNAs. To verify these hypotheses, it is necessary to 
study the behavior of the cells as exposed to the action 
of siRNAs for a longer period of time. Nevertheless, the 
data on long-term proliferation suppression may point 
to an important role played by the CCNB1 and PKC 
genes in the aggressive proliferation of SK-N-MC.
A study of the morphology of SK-N-MC cells 3–12 
days after transfection has demonstrated that tempo-
rary inhibition of the expression of the Her2, CCNB1, 
and PKC genes does not result in their death or ter-
minal differentiation (which is demonstrated by the 
retention of different cell types in the population) and 
slows cell division. The gradual increase in the total 
amount of cells in the preparations transfected with 38 | ACTA NATURAE |  VOL. 3  № 3 (10)  2011
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specific siRNAs and, in particular cells at the mitosis 
stage by days 10–12 of incubation, points to the fact 
that the duration of the antiproliferative effect of these 
siRNAs on neuroblastoma cells is likely limited to 12–
15 days.
In this study, it was demonstrated using genetic and 
morphological material that the Her2, CCNB1, and PKC 
genes are efficient targets for specifically addressed 
siRNAs in neuroblastoma cells, since the decrease in 
the expression level of target genes attained with their 
aid results in efficient and long-term proliferation in-
hibition. The use of siRNAs to control the growth of 
tumor cells that survive chemotherapy may become 
one of the aspects of a complex therapy upon cancer 
and neuroblastoma, in particular. Until recently, low-
molecular-weight compounds found empirically have 
been used as antitumor agents. Interfering RNAs have 
the potential to become the new generation of prepa-
rations that considerably outperform known ones in 
terms of specificity, efficacy, and nontoxicity. 
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